Medtronic has begun the global launch of its Contour 3D Annuloplasty Ring for the treatment of tricuspid valve disease.
The device is designed to restore normal valve function by remodelling the natural valve’s shape and size. It is approved for use in the US, Europe and several other countries.
Tricuspid dilation is a progressive disease that eventually leads to severe tricuspid regurgitation (TR), which occurs when the tricuspid valve leaflets do not close properly, allowing blood to flow opposite of the intended direction.
“The new Contour 3D ring will offer surgeons the opportunity to choose a three-dimensional remodelling tricuspid ring with a true anatomical profile. This will minimise stress of the valve leaflets and optimise valve performance,” said Prof. Rüdiger Lange, Director of Cardiovascular Surgery at The German Heart Centre in Munich, who collaborated with Medtronic and other physicians on the device.
The Contour 3D Annuloplasty Ring is the only remodelling ring that matches the shape of a healthy tricuspid valve, as determined through computed tomography (CT) images from normal tricuspid valves.
“With the Contour 3D Ring, as well as the recently launched Tri-Ad Adams Tricuspid Ring, Medtronic’s tricuspid valve repair product line is now the most complete portfolio available for cardiac surgeons,” said Shawn Monaghan, Vice President of Surgical Based Therapies for the Medtronic Structural Heart business.
“This portfolio was made possible in part by our acquisition of ATS Medical, and we look forward to continuing to be a leading provider of future surgical repair solutions that improve clinical outcomes for patients.”